source
- Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsIn vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.Fierce Biotech · 5d ago↗ source
- Updated: FDA adcomm backs popular wellness peptides, despite staff concernsAn FDA advisory committee voted to recommend expanding access to popular peptides used by health and wellness enthusiasts for repairing muscles, healing injuries, boosting metabolism and reducing i…Endpoints · 6d ago↗ source
- FDA to end pilot aimed at preventing production issuesThe FDA said it will end a pilot that was intended to help drugmakers proactively address production issues. Few companies took advantage of the program during its three-year run. In April 2027, th…